Oncology

In terms of safety, it was noted that repeated administration of CAR mRNA/LNP was well-tolerated by mice.

Review top news and interview highlights from the week ending Novmber 3, 2023.

The chief executive officer of Likarda discussed the company’s CSS technology and how it may reduce off-tissue effects.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

CARVac RNA vaccine may amplify the persistence of the BNT211 CAR T-cell therapy.

The assistant professor at MD Anderson Cancer Center discussed the EVEREST-1 clinical trial of A2B530.

The assistant professor at MD Anderson Cancer Center discussed factors to consider when trying to treat patients with gastrointestinal cancers with cell therapy.

Patient preferences should be considered when selecting the optimal treatment regimen for patients with relapsed/refractory follicular lymphoma, as both CD19-directed CAR T-cell therapies and CD20-targeted bispecific antibodies can be efficacious.

In light of the IND clearance, the company is planning to carry out plans for a phase 1 clinical trial (AMpLify) for adult patients with r/r AML.

The combo, termed MB-109, consists of the MB-108 oncolytic virus and MB-101 CAR T-cell therapy.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

October is National Breast Cancer Awareness Month, and thus serves as an additional moment to point to the progress made in cell and gene therapy development, as well as the lingering challenges.

The first patient will be treated with CTO1681 at UPMC Hillman Cancer Center.

Review top news and interview highlights from the week ending October 20, 2023.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The full data readout from the phase 1/2 clinical trial is expected in the first quarter of 2024.

The director of the Center for Immunity and Immunotherapies at Seattle Children's Research Institute discussed findings from several preclinical studies that could help bring engineered B-cell therapies to clinical trials.

The company noted that there have been no dose-limiting toxicities so far among the 3 patients in the cohort.

The term “immunotherapy” has quite a wide scope in cancer treatment. A lot of different therapies fall within the umbrella of immunotherapy, and two of the most successful are CAR T-cell therapies and immune checkpoint inhibitors.

Richard James, PhD, an associate professor at the University of Washington and a principal investigator at Seattle Children's Research Institute, discussed a potential alternative to T-cell therapy in cancer.

Biosyngen is also evaluating the CAR T-cell therapy BRG01 in a phase 1/2 trial for EBV-positive relapsed/metastatic nasopharyngeal carcinoma.

MT-601, in contrast to CAR-T therapies, is not genetically engineered.

Nadezhda Omelchenko, MD, a research associate at Cancer Center of Southern California in Santa Monica, discussed findings from patients treated with a combination therapy that included NK cell therapy SNK01.

Review top news and interview highlights from the week ending October 13, 2023.

The associate professor at the University of Washington, and principal investigator at Seattle Children's Research Institute discussed results from a leukemia mouse model.